West Pharmaceutical Services (WST) Cash from Restructuring (2018 - 2026)

West Pharmaceutical Services (WST) posted quarterly Cash from Restructuring of $1.0 million for Q2 2026, up 25.0% year-on-year from $800000.0 in Q2 2025, and up 11.11% on a QoQ basis from $900000.0 in Q1 2026.

West Pharmaceutical Services (WST) Cash from Restructuring (2018 - 2026) Analysis & Trends

West Pharmaceutical Services (WST) has reported Cash from Restructuring for 4 consecutive years, with $1.0 million the latest figure, recorded in Q2 2026.

  • Quarterly Cash from Restructuring rose 25.0% year-over-year to $1.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.5 million (up 118.75% YoY) and the FY2025 annual result came in at $5.4 million, changed N/A from the prior year.
  • Cash from Restructuring advanced to $1.0 million in Q2 2026 per WST's latest filing, from $900000.0 in the prior quarter.
  • Over the last five years, Cash from Restructuring for WST reached as high as $1.0 million in Q2 2026 and fell as low as $800000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alcon 32,734,969.19 Bn 32,734,967.53 Bn 1.53 Bn
2 Intuitive Surgical 117.50 Bn 112.41 Bn 1.96 Bn
3 Becton Dickinson 42.93 Bn 42.11 Bn 2.15 Bn
4 Medline 30.82 Bn 36.66 Bn 1.84 Bn
5 Resmed 27.90 Bn 26.23 Bn 890.98 Mn
6 West Pharmaceutical Services 26.76 Bn 26.23 Bn 329.20 Mn
7 Cooper Companies 15.30 Bn 15.16 Bn 735.40 Mn
8 Solventum 13.46 Bn 12.90 Bn 1.10 Bn
9 Align Technology 12.02 Bn 10.96 Bn 736.59 Mn
10 Baxter International 11.17 Bn 9.12 Bn 891.00 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 1.00 Mn
Mar 31, 2026 900,000.00
Jun 30, 2025 800,000.00
Mar 31, 2025 800,000.00
Dec 31, 2019 700,000.00
Sep 30, 2019 1.20 Mn
Jun 30, 2019 100,000.00
Mar 31, 2019 300,000.00
Dec 31, 2018 1.40 Mn
Sep 30, 2018 400,000.00
Jun 30, 2018 300,000.00
Mar 31, 2018 100,000.00